PubMed Health⌕ Search

Biomedical subjects

P Albrecht-van Lent

Publications and source records attributed to P Albrecht-van Lent.

5 recordsLinked to original sources
PubMed1986

Introduction of lymphadenopathy associated virus or human T lymphotropic virus (LAV/HTLV-III) into the male homosexual community in Amsterdam.

To establish when lymphadenopathy associated virus or human T lymphotropic virus (LAV/HTLV-III) was introduced into the Netherlands, we studied a cohort of homosexual men who participated in a hepatitis B vaccine efficacy study between 1980 and 1982. On entry into the study (November 1980 to December 1981) five (0.7%) out of 685 participants were found to have antibodies to LAV/HTLV-III, and during follow up 15 seroconversions were detected among the 680 who had been seronegative initially (end point attack rate 3%). LAV/HTLV-III was not transmitted by the heat inactivated hepatitis B virus (HBV) vaccine used. Anal sexual contact and antibodies to cytomegalovirus (CMV) were found to correlate with seropositivity or seroconversion for LAV/HTLV-III. Six out of 15 men who seroconverted reported a mononucleosis like illness, but three of them had other concurrent virus infections. To date, only one of the 20 seropositive men has developed the acquired immune deficiency syndrome (AIDS), three years after his seroconversion. This study shows that the introduction of LAV/HTLV-III into the Dutch male homosexual community took place at the end of the 1970s, a few years before the first case of AIDS in a native Dutchman.

Acquired Immunodeficiency Syndrome↗
PubMed1984

Infection with cytomegalovirus in homosexual men.

The prevalence and incidence of cytomegalovirus (CMV) infections were studied in a group of homosexual men. Of the 710 participants, 501 (70.6%) had complement fixing antibodies to CMV on entry to the study. During the follow up (maximum 23 months) 69 CMV infections were found: 50 primary infections among the 209 seronegative men (attack rate 27.3%), and 19 recurrent infections among the 501 seropositive men (attack rate 6.2%). The prevalence of antibody to CMV was correlated with four characteristics of the participants' lifestyles: duration of homosexual activity, number of different sexual partners, history of syphilis, and anal sexual contact. Among the seronegative men, the incidence of primary infection with CMV correlated with a history of syphilis and anal sexual contact. We conclude that infections with CMV are highly prevalent among homosexual men, and that anal sexual contact plays an important part in the transmission of this virus.

Adult↗
PubMed1983

Prevalence and incidence of hepatitis A among male homosexuals.

In a study of 689 male homosexuals 290 (42%) were found to have antibodies to hepatitis A virus. The 399 men who did not have antibodies were followed up for up to 690 days, and 35 cases of hepatitis A were detected. The attack rate at the end of the study was 14%. The incidence climbed steadily, indicating that the cases of hepatitis A did not occur in clusters. Statistical analysis showed that the prevalence of antibodies to hepatitis A virus was significantly correlated with the duration of homosexual activity (p less than 0.006), and this was independent of age. The incidence of hepatitis A was found to be correlated with the number of different sexual partners in the preceding six months. It is concluded that hepatitis A is a sexually transmitted disease among homosexual men in countries with a low rate of exposure to hepatitis A during childhood.

Adolescent↗
PubMed1983

Efficacy trial of heat-inactivated hepatitis B vaccine (CLB) in male homosexuals in the Netherlands.

The efficacy of a heat-inactivated hepatitis B virus (HBV) vaccine, containing 3 micrograms-HBsAg, was studied among a group of 800 susceptible homosexual men. The trial was conducted randomized, placebo-controlled and double blind. At the trial end point (21.5 months) the attack-rate for all HBV infections together was 4.8% among vaccinees and 23.8% among the placebos (p less than 0.0001). Four months after the first injection 89% of the vaccinees had formed anti-HBs and this percentage declined only slightly during the follow-up period. Maximum titers were reached 5 months after the first vaccination. None of the vaccinees who responded to the vaccine with anti-HBs greater than or equal to 1 mIU/ml developed a HBsAg positive infection. The vaccine had no serious side-effects.

Clinical Trials as Topic↗